Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials

References

• World Health Organization. Obesity and overweight. Geneva: WHO; 2017.
   Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–1396.
   PubMed Web of Science ®Google Scholar
• Hales CM, Fryar CD, Carroll MD, et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA. 2018;319:1723–1725.
   PubMed Web of Science ®Google Scholar
• NHS Digital. Statistics on obesity, physical activity and diet - England, 2018. NHS Digital; 2018. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-obesity-physical-activity-and-diet/statistics-on-obesity-physical-activity-and-diet-england-2019 (Accessed July 30, 2019).
   Google Scholar
• Després JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716–720.
   PubMedGoogle Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63:2895–3023.
   Web of Science ®Google Scholar
• Burke LK, Heisler LK. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol. 2015;27:389–398.
   PubMed Web of Science ®Google Scholar
• Valencia-Torres L, Olarte-Sanchez CM, Lyons DJ, et al. Activation of ventral tegmental area 5-ht2c receptors reduces incentive motivation. Neuropsychopharmacology. 2017;42:1511–1521.
   PubMed Web of Science ®Google Scholar
• Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–845.
   PubMed Web of Science ®Google Scholar
• Apovian C, Palmer K, Fain R, et al. Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies. Diabetes Obes Metab. 2016;18(9):945–948.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA briefing document, NDA 22529. Advisory committee meeting for lorcaserin. Endocrinologic & Metabolic Drugs Advisory Committee; 2010 Sept 16; [cited 2019 Jul]. Available from: http://www.sefap.it/farmacovigilanza_news_201011/UCM225631.PDF
   Google Scholar
• Food and Drug Administration: FDA news release. FDA approves Belviq to treat some overweight or obese adults. 2012Jun 27; [cited 2019 Jul]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 309993.htm
   Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity. 2009;17:494–503.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–1436.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107–1117.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Scirica BM, Inzucchi SE, et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018;392(10161):2269–2279.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bohula EA, Dwyer JP, et al. Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019;139(3):366–375.
   PubMed Web of Science ®Google Scholar
• Chan EW, He Y, Chui CS, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obesity Rev. 2013;14(5):383–392.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Chatterjee S, O’Keefe JH, et al. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart. 2014;1:e000173.
   PubMedGoogle Scholar
• Kuo HH, Wang KT, Lee YH, et al. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. J Clin Pharm Ther. 2019 Sep 23. DOI:10.1111/jcpt.13047.
   PubMed Web of Science ®Google Scholar
• Sachdev M, Miller WC, Ryan T, et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J. 2002 Dec;144(6):1065–1073.
   PubMed Web of Science ®Google Scholar
• Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol. 2002;2:6.
   PubMedGoogle Scholar
• Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897–902.
   PubMed Web of Science ®Google Scholar
• Smith SR, Garvey WT, Greenway FL, et al. Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study. Obesity. 2017;25:857–865.
   PubMed Web of Science ®Google Scholar
• Shaw Tronieri J, Wadden TA, Berkowitz RI, et al. A randomized trial of lorcaserin and lifestyle counseling for maintaining weight loss achieved with a low-calorie diet. Obesity. 2018;26(2):299–309.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of belviq XR® in conjunction with lifestyle modification for weight loss in obese adolescents, age 12 to 17 years. `cited 2019 Jul]. Available from: https://clinicaltrials.gov/ct2/show/NCT03338296
   Google Scholar